Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
September, 2024
September 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« Aug
NCCN
Sep 22, 2024, 15:15 |
Insight
Dexamethasone reduces IRRs in patients with EGFR-mutated NSCLC treated with intravenous RYBREVANT
Johnson and Johnson announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional…
Sep 21, 2024, 10:20 |
Societies
Best of World Cancer Congress 2024
The WCC24 took place at the International Conference Centre of Geneva, Switzerland, from 17 to…
Sep 20, 2024, 09:38 |
Blog
Toni Choueiri: Surrogate markers of survival in kidney cancer
Toni Choueiri posted on X: "Work from the IMDC database looking at surrogate markers of…
Sep 18, 2024, 22:59 |
Insight
Rami Manochakian: Ponsegromab vs Placebo for treatment of Cachexia in patients with Cancer
Rami Manochakian shared a post on X about a recent paper by John Groarke et…
Sep 17, 2024, 15:01 |
Blog
Rebecca Shatsky: Post-breast session at ESMO24
Rebecca Shatsky shared a post on X: ''Post-breast session at ESMO24. With the beloved Kevin…
Sep 14, 2024, 15:33 |
Insight
Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma
Toni Choueiri shared a post on X about a recent paper by Brian Shuch et…
Sep 13, 2024, 23:13 |
Insight
Combining PSMA-PET and PROMISE to re-define disease stage and risk in prostate cancer - APCCC
Advanced Prostate Cancer Consensus Conference posted the following on LinkedIn: “Combining PSMA-PET and PROMISE to…
Sep 12, 2024, 17:16 |
Insight
Yüksel Ürün: Omitting the 5-FU bolus from regimens in metastatic GI cancers may reduce toxicity without impacting overall survival
Yüksel Ürün shared on X: "Omitting the 5-FU bolus from regimens like FOLFOX, FOLFIRI, and…
Sep 12, 2024, 15:38 |
Blog
National Comprehensive Cancer Network is accepting original abstracts for the General Poster Session
National Comprehensive Cancer Network shared a post on LinkedIn: 'The NCCN Annual Conference features the General…
Sep 11, 2024, 16:13 |
Insight
RYBREVANT plus LAZCLUZE versus osimertinib in EGFR-mutated advanced lung cancer
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT plus LAZCLUZE regimen compared…
3
4
5
6
7
All:
276
Posts:
41 - 50
Jeff Bridges and Lymphoma: How He Went Against, How He Survived, and More
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 5
Familial Adenomatous Polyposis: Alarming Symptoms, Causes, Types, Diagnosis and Treatment
OncoDaily Party Barcelona
Ben Stiller and Prostate Cancer: How He Went Against, How He Survived, and More
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube